April 2016

New Product - Cortiment

Cortiment (budesonide) inhibits many inflammatory processes including cytokine production, inflammatory cell activation and expression of adhesion molecules on endothelial and epithelial cells. Cortiment is indicated in adults for induction of remission of mild to moderate active ulcerative colitis where 5-ASA treatment is not sufficient or not tolerated. It is contraindicated with peanut oil hypersensitivity. Cortiment is available as 9 mg prolonged release tablets in packs of 10’s and 30’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629